1The International HapMap Consortium. The International HapMap Project. Nature, 2003,426:789--796.
2Whiteside T L, Rabinovcich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother, 1998,46:175 -184.
3Leithauser F, Dhein J, Mechtersheimer G,et al. Constitutive and induced expression of APO 1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest, 1993,69 : 415-- 429.
4Evan G I, Vousden K H. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001,411:342--348.
5Nagata S, Golstein P. The Fas death factor. Science, 1995, 267: 1449-- 1456.
6Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol, 2002,12 : 309-- 315.
7Kase H, Aoki Y, Tanaka K. Fas ligand expression in cervical adenocarcinoma: relevance to lymph node metastasis and tumor progression. Gynecol Oncol, 2003,90 :70-- 74.
8Ropponen K M, Eskelinen M J, Lipponen P K, et al. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol,1997,182:318--324.
9MuschenM, Warskulat U, BeekmannMW. Defining CD95 as a tumor suppressor gene. J Mol Med, 2000, 78: 312--325.
10Kurooka M, Nuovo G J, Caligiuri M A, et al. Cellular localization and function of Fas ligand (CD95L) in tumors. Cancer Res, 2002,62 : 1261-- 1265.
3Butler LM, Hewer PJ, Butler WJ, Cowled PA. Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br J Cancer,1998,77:1454-1459.
4Belluco C, Esposito G, Bertorelle R, Alaggio R, Giacomelli L,Bianchi LC, Nitti D, Lise M. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol, 2002,28 : 120-125.
5Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst,2004 ,96 :1030-1036.
6Lee SH, Shin MS, Park WS, Kim SY, Kim SH, Han JY, et al.Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene,1999. 18 : 3754-3760.
7Kase S, Osaki M, Adachi H, Tsujitani S, Kaibara N, ho H.Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oneol,2 002,20: 291-297.
8Evan GI, Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature,2001, 17: 342-348.
9Suda T, Takahashi TI Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell,1993,75:1169-1178.
10Nagata S, Golstein P. The Fas death factor. Science, 1995, 267:1449-1456.
5Gillenwater AM,Zhong ML,Lotan R.Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells[J].Mol Cancer Ther,2007,6:2967.
6Hwang JT,Ha J,Park IJ,et al.Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway[J].Cancer Lett,2007,247(1):115.
7Makinen K,Sami L,Tapio H,et al.Tumour suppressor protein (p53),apoptosis inhibiting protein (Bcl-2) and proliferating cell nuclear antigen (PCNA) expressions in a rat pancreatic tumour model[J].Anticancer Res,2007,27:23.
8Malkas LH,Herbert BS,Abdel-Aziz W,et al.A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker[J].PNAS,2006,103(51):19472.
9Jacobson PB;Borgan SJ;Wilcox DM.A new spin on an old model:in vivo eveluation of disease progress by magnetis resonance imaging with respect to standard inflammatory parameters and histopthology in adjuvant arthritic rat.,1999(10).
